GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment

Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Today
—
Total
BSE
Exchange
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Corona Remedies Ltd
Corona Remedies Board Meeting Scheduled for Q2 FY27 Unaudited Results
RESULTS ● No Immediate Change LOW RISK
📅 Filed on BSE: 16 Oct 2026, 12:22 PM IST  ·  BSE ID: 4d2fddfa-1a5e-4f2c-8f89-135376c0dcde
View Original BSE Filing (PDF)
💡
In Simple Terms
Corona Remedies will hold a board meeting on October 30, 2026, to approve its financial results for the last quarter.
🤖 AI Summary
  • Board of Directors meeting scheduled for Friday, October 30, 2026.
  • Purpose is to consider and approve Unaudited Financial Results for Q2 and half year ended September 30, 2026.
  • Trading window for company securities remains closed until Sunday, November 01, 2026.
  • Intimation issued pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
👥 What This Means For Shareholders
✅
Action Required
No action is required from shareholders based on this intimation of a board meeting.
👤
Who Is Affected
All shareholders are affected as the upcoming financial results will provide an update on the company's performance. Insiders are restricted from trading company securities until November 01, 2026.
🔍
Management Signal
The management is adhering to regulatory requirements by intimating the board meeting for financial results approval and closing the trading window.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Outcome of Board Meeting on October 30, 2026, for Q2 FY27 results.
Detailed Unaudited Financial Results for Q2 and H1 FY27.
Reopening of trading window after November 01, 2026.
LOW RISK This filing is a routine board meeting intimation, carrying no inherent immediate risks.
💡 Investor Takeaway
Corona Remedies Ltd. has scheduled a Board meeting on October 30, 2026, to consider and approve Unaudited Financial Results (Standalone and Consolidated) for the second quarter and half year ended September 30, 2026. The trading window is closed until November 01, 2026.
📅 Company Track Record
Corona Remedies reported Q1 FY27 revenue up 21.9% to ₹ 422.4 Cr and PAT up 30.1% on July 31, 2026. For the full FY26, revenue was up 17.3% to ₹1,403.2 Cr and PAT was up 33.4%, as reported on May 11, 2026. A final dividend of ₹10 per equity share was also recommended for FY26.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
When is the next Board Meeting for Corona Remedies Ltd?
The next Board Meeting for Corona Remedies Ltd is scheduled for Friday, October 30, 2026.
What is the purpose of the upcoming Board Meeting for Corona Remedies?
The Board Meeting is to consider and approve the Unaudited Financial Results (Standalone and Consolidated) for the second quarter and half year ended September 30, 2026.
When does the trading window close for Corona Remedies Ltd securities?
The trading window for dealing in Corona Remedies Ltd securities remains closed till Sunday, November 01, 2026.
Which SEBI Regulation is cited for this Board Meeting intimation?
The intimation of the Board Meeting is pursuant to Regulation 29 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Questions based on this BSE filing only. For information purposes.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.